MAGGI, CLAUDIA
 Distribuzione geografica
Continente #
EU - Europa 2.189
NA - Nord America 1.718
AS - Asia 1.416
SA - Sud America 110
AF - Africa 33
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.484
Nazione #
US - Stati Uniti d'America 1.671
DE - Germania 1.064
CN - Cina 492
GB - Regno Unito 439
SG - Singapore 394
IT - Italia 160
SE - Svezia 159
HK - Hong Kong 137
VN - Vietnam 126
RU - Federazione Russa 95
BR - Brasile 83
BD - Bangladesh 81
FR - Francia 69
NL - Olanda 58
IE - Irlanda 42
FI - Finlandia 38
IN - India 38
CA - Canada 36
ID - Indonesia 28
JP - Giappone 24
TR - Turchia 23
KR - Corea 19
AU - Australia 16
UA - Ucraina 14
CI - Costa d'Avorio 11
BE - Belgio 10
PL - Polonia 10
AR - Argentina 9
IQ - Iraq 9
TH - Thailandia 9
DK - Danimarca 6
MX - Messico 6
AT - Austria 5
EC - Ecuador 5
ES - Italia 5
IR - Iran 4
JO - Giordania 4
KE - Kenya 4
UZ - Uzbekistan 4
CH - Svizzera 3
CO - Colombia 3
DZ - Algeria 3
MA - Marocco 3
PK - Pakistan 3
SA - Arabia Saudita 3
TW - Taiwan 3
VE - Venezuela 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
IL - Israele 2
KG - Kirghizistan 2
PT - Portogallo 2
SN - Senegal 2
AM - Armenia 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KW - Kuwait 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SR - Suriname 1
SV - El Salvador 1
TL - Timor Orientale 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 5.484
Città #
Frankfurt am Main 955
Southend 398
Singapore 240
Ashburn 219
Chandler 175
Hong Kong 131
Beijing 104
San Jose 94
Seattle 90
Milan 87
Fairfield 84
Dallas 59
Wilmington 54
Council Bluffs 49
Munich 48
Princeton 48
Cambridge 46
Houston 46
Los Angeles 44
Dublin 40
Woodbridge 40
New York 39
Ho Chi Minh City 38
Phoenix 32
Santa Clara 32
Hanoi 29
Lauterbourg 24
Nanjing 23
Ann Arbor 22
Dearborn 22
Moscow 21
Columbus 20
Guangzhou 20
Toronto 20
Buffalo 19
Des Moines 19
Jakarta 18
Shanghai 18
Tokyo 18
Istanbul 16
Shenyang 16
San Diego 15
The Dalles 15
Da Nang 14
Eitensheim 14
Bengaluru 13
Zhengzhou 13
Helsinki 12
Jinan 12
Abidjan 11
Hangzhou 11
Brussels 9
Changsha 9
Chicago 9
Nanchang 9
Cangzhou 8
Falls Church 8
Grafing 8
Redwood City 8
Amsterdam 7
Boardman 7
Fuzhou 7
Newark 7
Silver Spring 7
São Paulo 7
Bexley 6
Hebei 6
Stockholm 6
Sydney 6
Taiyuan 6
Tianjin 6
Turku 6
Bangkok 5
Düsseldorf 5
Montreal 5
Naples 5
Orem 5
Warsaw 5
Amman 4
Andover 4
Baghdad 4
Brooklyn 4
Haikou 4
Hefei 4
Jiaxing 4
Kunming 4
Manchester 4
Nairobi 4
Ningbo 4
Nuremberg 4
Piscataway 4
Rio de Janeiro 4
San Francisco 4
Shenzhen 4
Wroclaw 4
Atlanta 3
Bari 3
Biên Hòa 3
Brasília 3
Charlotte 3
Totale 3.912
Nome #
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase 336
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab : A clinical and translational study 327
Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies 304
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status 299
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer : a Retrospective Comparison of Efficacy and Safety Profiles 269
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan 268
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer 252
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation 252
Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens 243
TP53 mutations in advanced colorectal cancer : the dark side of the moon 240
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma 235
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives 231
Role of cMET in the development and progression of colorectal cancer 229
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis 228
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases 227
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis 226
Role of MGMT as biomarker in colorectal cancer 212
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil : a meta-analysis of published trials 210
Bevacizumab treatment in the elderly patient with metastatic colorectal cancer 209
Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer : A systematic review and meta-analysis of published trials 196
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer : an Italian Trials of Medical Oncology phase II study 192
Treatment of elderly patients with metastatic renal cell carcinoma 171
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab 170
In reply 162
Totale 5.688
Categoria #
all - tutte 13.063
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.063


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 0 21 15
2021/2022310 56 10 5 13 20 16 13 13 21 55 13 75
2022/2023508 58 68 55 46 50 85 5 35 77 5 16 8
2023/2024908 4 20 15 8 78 16 137 126 68 156 136 144
2024/20251.066 130 115 101 129 51 28 25 73 39 107 78 190
2025/20261.456 183 86 158 110 149 94 211 45 118 82 220 0
Totale 5.688